Auffarth Gerd 4
4 · Outlook Therapeutics, Inc. · Filed Oct 3, 2024
Insider Transaction Report
Form 4
Auffarth Gerd
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-10-01+56,636→ 56,636 totalExercise: $5.22Exp: 2034-10-01→ Common Stock (56,636 underlying) - Award
Stock Option (Right to Buy)
2024-10-01+29,493→ 29,493 totalExercise: $5.22Exp: 2034-10-01→ Common Stock (29,493 underlying) - Award
Stock Option (Right to Buy)
2024-10-03+12,082→ 12,082 totalExercise: $5.25Exp: 2034-10-03→ Common Stock (12,082 underlying)
Footnotes (3)
- [F1]This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
- [F2]This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
- [F3]The options were granted under the 2024 Plan in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.